Arvinas-JPM-202401 .pdf

1、 2024 Arvinas.All rights reserved.Pioneering Today with a different kind of medicineTransforming Tomorrow for patients who need usJanuary 2024NASDAQARVNL I S T E DSafe harbor and forwardSafe harbor and forward-looking statementslooking statements2This presentation contains forward-looking statements

2、 within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties,including statements regarding our expectation of brining the first PROTACT protein degrader to market in partnership with Pfizer;the timing for our first neuroscience PROTAC

3、degrader to enter the clinic;the timing of presenting Phase 3 clinical trial topline data for vepdegestrant and our plans related to commercial launch of vepdegestrant;the plans for and anticipated timings related to our planned clinical trials and/or data read outs from such trials,including second

4、-line Phase 3 clinical trials of vepdegestrant in combination with palbociclib and potentially other CDK4/6 inhibitors,a first-line Phase 3 clinical trial of vepdegestrant in combination with a CDK4 inhibitor,our Phase 3 clinical trial for ARV-766 as a monotherapy,and our Phase 1 dose escalation tri

5、als of ARV-393(BCL6)and ARV-102(LRRK2);the potential for vepdegestrant as an oral best-in-class targeted therapy and to become a backbone estrogen receptor therapy in the metastatic breast cancer space;the potential therapeutic benefits and market opportunity of our product candidates,including vepd

6、egestrant,ARV-766,ARV-393 and ARV-102;the opportunity for ARV-766 in both post-and pre-novel hormonal agent settings to potentially treat metastatic castrate-sensitive prostate cancer and metastatic castrate-resistant prostate cancer;the potential for androgen receptor(AR)-targeting PROTAC degraders